The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2020

Filed:

Jun. 22, 2017
Applicants:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Universite DE LA Reunion Saint Denis, Saint Denis, FR;

Institut DE Recherche Pour Le Developpement (Ird), Marseilles, FR;

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Inventors:

Philippe Despres, Sainte Clotilde la Reunion, FR;

Gilles Gadea, Sainte Clotilde la Reunion, FR;

Patrick Mavingui, Sainte Clotilde la Reunion, FR;

Wildriss Viranaicken, Sainte Clotilde la Reunion, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); A61K 39/39 (2006.01); A61K 35/76 (2015.01); A61P 31/14 (2006.01);
U.S. Cl.
CPC ...
A61K 35/76 (2013.01); A61K 39/12 (2013.01); A61P 31/14 (2018.01); A61K 2039/5254 (2013.01); C12N 2770/24121 (2013.01); C12N 2770/24134 (2013.01); Y02A 50/392 (2018.01);
Abstract

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.


Find Patent Forward Citations

Loading…